Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment
2010; Taylor & Francis; Volume: 17; Issue: 2 Linguagem: Inglês
10.3109/13506129.2010.483121
ISSN1744-2818
AutoresMerrill D. Benson, Richard Smith, Gene Hung, Barbara Kluve‐Beckerman, Aaron D. Showalter, Kyle W. Sloop, Brett P. Monia,
Tópico(s)Ion channel regulation and function
ResumoLeptomeningeal amyloidosis associated with mutations in transthyretin (TTR) is a rare but fatal form of amyloidosis. Dementia and intracerebral haemorrhage are prominent features of this disease for which no specific therapy is known. In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Parenteral administration of TTR-specific ASO, however, had no effect on the expression of TTR by the choroid plexus, which is believed to be the source of the amyloid protein in patients who have leptomeningeal amyloidosis. In the present study, mice transgenic for the human TTR amyloid-associated mutation Ile84Ser were treated by administration of TTR-specific ASO (50 μg or 75 μg per day) via an osmotic pump into the cerebral ventricular system over a 4-week period. Intraventricular administration of TTR-specific ASO significantly reduced choroid human TTR mRNA levels, and these findings correlated with decreased TTR in choroid plexus epithelial cells as demonstrated by immunohistochemistry. Suppression of choroid TTR expression by intraventricular administered ASO may offer a medical means of treating leptomeningeal amyloidosis.
Referência(s)